What's Hot
View all perspectives
Dr. Jason J Lee (이주헌)
1 year ago
Shout out to @RheumNow, @Janetbirdope, @drdavidliew, and @EBRheum for amazing coverage of #ACR23! I am sad to be missing it in person, but have my finger on the pulse of Rheumatology this year via these savvy experts. Thank you!
Eric Dein
1 year ago
AI predict ANA specific Abs? @AliDuarteMD
Ab#0852 #ACR23 @RheumNow
410K pts test for ANA HEp-2 IFA (136K pos, 47K specific autoAb)
AI prediction models >0.80 AUC exc for RNP, Scl70
More predictive than traidtional staining patterns (p<0.001), except centromere (similar) https://t.co/4ZvP79rEdl
David Liew drdavidliew
1 year ago
TLL-018, the dual JAK1/Tyk2 inhibitor which caused all the chatter at #EULAR2023, now with more full data showing it absolutely smash tofacitinib in RA, with similar safety.
“This is a spectacular compound - unbelievably spectacular” - Roy Fleischmann
#ACR23 ABST0840 @RheumNow https://t.co/nIKQb4yYrJ
David Liew drdavidliew
1 year ago
More on TLL-018
How?
A: Everyone surprised. But maybe dual mech benefits re: pain via IFN
Where’s the multinational RCT in RA?
A: Priority on rapid registration in China, quickly. But ph2 trials for psoriasis happening in US, results so far look consistent.
#ACR23 @RheumNow
Aurelie Najm
1 year ago
What if we deliver TNFi to the wrong place?
Delivery of ETA to peripheral lymphatics instead of subcut through a wearable device in 10pts showed:
1- is Safe
2-Reduces DAS28 (but more TJC than SJC)
To be confirmed in larger and controlled study!
@RheumNow #ACR23 ABST0838 https://t.co/IUPpFwjjbj
David Liew drdavidliew
1 year ago
Colchicine - what a fascinating medicine.
From a rheum point of view, interesting to see it play out for secondary prevention coronary artery disease, lot of patients. Great we can share our collective clinical confidence with it with cardiology
#ACR23 @US_FDA session @RheumNow https://t.co/Q7zLtyby8l
sheila
1 year ago
Results of this study by Dr Fava show that most urinary BMs of histological activity were⬆️at 6 & 12mos in pts who lost GFR at 3yrs.
☝️Some LN pts still develop renal damage despite clinical response. Is there a role for BMs in monitoring tx?
#ACR23 ABST0850 @RheumNow #ACRbest https://t.co/H5G6LJ22lw
Richard Conway
1 year ago
Taylor et al. Positive phase 2 RCT of Nipocalimab (neonatal Fc receptor blocking monoclonal) in RA. Abstr#0839 #ACR23 @RheumNow https://t.co/UHjti200yh https://t.co/tkSlLMIl7X
Aurelie Najm
1 year ago
Ph2a Nipocalumab: FcRn blocker
IV15mg/kg TNF IR RA 32 pts
Delta DASCRP -1 vs -0.5 PBO
ACR50 20% vs 0 PBO
DAS Remission 40% vs 16% Only in ACPA+ pts
SAEs 1 infusion related reaction
Not extremely convincing alone
Currently studied in combination w/ TNFi
@RheumNow #ACR23 ABST0839 https://t.co/6wTu2ellhN
Robert B Chao, MD
1 year ago
Utility of repeating assessments in chronic back pain pts suspected of early axSpA?
2 year study found a modest increase in new axSpA diagnosis after 2 years
Yield of repeating MRI is low but can be considered in B27+ males
@RheumNow #ACR23 Abs#0845 https://t.co/TgSEztUkTm
Few people are aware of the EULAR recommendations for cardiovascular risk management in SLE published in 2022. The recommendations had 4 overarching principles: increase awareness of elevated cardiovascular risk, need for regular cardiovascular screening, assess and manage modifiable risk factors, and patient education. During ACR 2023 Convergence, several abstracts were presented evaluating the prevalence of CV disease and exploring new
Dr. John Cush RheumNow
1 year ago
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Richard Conway
1 year ago
Ross et al. Fascinating study of infusion of etanercept into lymphatics in RA in inadequate responders to s/c etanercept. DAS28(CRP) reduced 5.40±0.16 to 3.55±0.21, PGA of Disease Activity and Pain decreased by 66% and 77%. Abstr#0838 #ACR23 @RheumNow https://t.co/RIMCS3nmy6 https://t.co/U2689atvmj
Poster Hall